National approval for MOB-015 in all 13 countries
STOCKHOLM, May 6[th], 2024, Moberg Pharma AB (OMX:MOB) hereby announces that MOB-015 has received national approvals for all countries included in the decentralized procedure. MOB-015 is thus approved for the treatment of mild to moderate fungal infections of the nails in adults in 13 European countries.National approvals follow the completion of the decentralized procedure with a positive result where MOB-015 is recommended for approval in 13 European countries, see press release from June 28[th], 2023. The following EU countries are included: Austria, Belgium, Czech Republic, Denmark,